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Management of infections due to carbapenem-resistant Gram-negative bacteria (CRGNB) is a therapeutic challenge.\[[@ref1][@ref2][@ref3]\] Colistin-based combination therapy (CCT) is a popular strategy employed against these infections. There are multiple studies and systematic reviews supporting this approach.\[[@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10]\] On the contrary, a meta-analysis of all the available combination studies questioned the effectiveness of combination strategy.\[[@ref11]\] A retrospective study of colistin monotherapy (CMT) versus CCT against CRGNB bloodstream infections from our own center revealed equivalence of both approaches, except in a subgroup of neutropenic patients with Enterobacteriaceae infections where CCT arm performed better.\[[@ref12]\] There are no published data from India comparing CCT and CMT against CRGNB nonbacteremic infections.

The aim of the present study was to analyze the effectiveness of both strategies against CRGNB nonbacteremic infections.
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Retrospective analysis of patients who had carbapenem-resistant Gram-negative (CRGNB) nonbacteremic infections identified over a period of 4 years (January 2012--December 2015) was done by medical record review at a 300-bedded tertiary care oncology, neurosurgical and orthopedic center in India. The Institutional Ethics Committee approved this study. As the study design was retrospective observational, informed consent was waived.

Bacterial identification and susceptibility were done using VITEK-2 compact system (bioMérieux, France). Susceptibility results were interpreted according to the Clinical and Laboratory Standards Institute guideline. CRGNB was defined as resistant to imipenem and/or meropenem *in vitro*. Colistin susceptibility was tested using VITEK-2 compact for all isolates, and minimum inhibitory concentration was calculated for some isolates by *E*-test according to availability. Hospital identification numbers of patients with CRGNB nonbacteremic infections were recovered from hospital digital database, and their medical records were tracked and analyzed.

A patient is considered cured from infection if there is microbiological cure or no additional antibiotic therapy for the targeted infection necessary. Patients were classified as having nonbacteremic CRGNB infection if: (a) there was recovery of a CRGNB isolate from cultures of intra-abdominal wounds, urine, respiratory tract specimens (sputum, endotracheal aspirate, or bronchoalveolar lavage fluid), or other sites; (b) there was no blood culture positivity for CRGNB for the duration of hospitalization; (c) there were clinical signs of infection; and (d) patients were receiving treatment with an antimicrobial regimen that was consistent with the isolate\'s *in vitro* susceptibility profile.\[[@ref13]\]

Data for variables such as age, sex, underlying immunocompromising condition, comorbidities, Intensive Care Unit (ICU) stay, duration of the first isolate from admission, colistin administration within 24 h of index date of sample collection, colistin dose, duration and cumulative dose, presence of indwelling devices, and prior antibiotic exposure were looked into.\[[@ref12]\] Charlson comorbidity index was calculated for all patients. Acute Physiology and Chronic Health Evaluation II (APACHE II) score was calculated for ICU patients. The outcome including 28-day mortality was analyzed. Antimicrobial therapy was considered appropriate if the regimen included antibiotics that were active *in vitro*. Those patients who received colistin, carbapenem, or tigecycline for \<72 h were excluded from the study. Neutropenia was defined as a neutrophil count lower than 1000/mm^3^. Treatment given before obtaining susceptibility results was defined as empirical. An empirical antimicrobial treatment regimen was considered as inadequate if it did not include at least one drug displaying *in vitro* activity against the CRGNB isolate. Regimens were classified as CMT or CCT depending on whether the patient received colistin alone or any other antibiotics included in the study (carbapenem, aminoglycoside, and tigecycline).

Statistical analysis was performed using SPSS 16.0. *P* \< 0.05 was considered as statistically significant.\[[@ref12]\] Multivariate analysis using Cox regression was performed, incorporating univariate variables with *P* \< 0.05, for 28-day mortality. All categorical variables were represented by percentages. Continuous variables were represented by mean ± standard deviation. Comparison of categorical variables was done by Chi-square test or Fisher\'s exact test.
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Out of 153 patients (pneumonia 115, urinary tract infection 17, complicated skin and soft-tissue infection 18, intra-abdominal infection 1, and meningitis 2), 92 patients received CCT and 61 received CMT. *Acinetobacter baumannii* was the causative organism in 35% of the patients, *A. baumannii* and *Klebsiella pneumoniae* in 3%, *Escherichia coli* in 5%, *K. pneumoniae* in 42%, and *Pseudomonas aeruginosa* in 15%. Out of the 92 patients who received CCT, 24 had *Acinetobacter* and received colistin--carbapenem (ColCarb) combination in 15, colistin--carbapenem--tigecycline (ColCarbTig) in 2, colistin--carbapenem--tigecycline--sulbactam (ColCarbTigS) in 4, and colistin--carbapenem--sulbactam (ColCarbS) in 3. Two patients in combination arm had mixed infection with carbapenem-resistant *Acinetobacter* and *Klebsiella* (both received colistin and carbapenem). Out of the 6 patients with *E. coli* in CCT arm, 3 had ColCarb and 3 had ColTig. Out of 47 *Klebsiella*, 28 had ColCarb, 8 ColCarbTig, and 11 ColTig. All the 13 *Pseudomonas* in the CCT arm received ColCarb combination.

Crude mortality was high in the CCT arm (38% \[35/92\]) compared to the monotherapy arm (18% \[11/61\]), but CCT arm had sicker patients with more number of patients in ICU and on inotropes (92.4% vs. 73.8%, *P* = 0.002, 37% vs. 16.4%, *P* = 0.006, respectively). Characteristics of patients are shown in [Table 1](#T1){ref-type="table"}.

###### 

Characteristics of patients with nonbacteremic infections due to carbapenem-resistant Gram-negative bacteria
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Univariate and multivariate Cox regression analyses for all-cause 28-day mortality were done \[[Table 2](#T2){ref-type="table"}\]. Univariate analysis revealed that a higher APACHE II score of \>24 (odds ratio \[OR\] =2.975, 95% confidence interval \[CI\] = 1.075--8.235; *P* = 0.036), pneumonia as the syndromic diagnosis (OR = 4.465, 95% CI = 1.543--12.917; *P* = 0.006), and *Klebsiella* as the etiological agent (OR = 3.536, 95% CI = 1.269--9.856; *P* = 0.016) were significantly associated with higher 28-day mortality. Colistin administration on the index date (OR = 1.935, 95% CI = 0.737--5.078; *P* = 0.18) and combination therapy (OR = 0.91, 95% CI = 0.327--2.535; *P* = 0.857) did not have any protective effect on the 28-day mortality. Multivariate analysis revealed that high APACHE II score (OR = 3.16, 95% CI = 1.34--7.4; *P* = 0.0080) and *Klebsiella* as the etiological agent (OR = 4.9, 95% CI = 2.19--11.2; *P* = 0.0001) were independently associated with higher 28-day mortality. As the sample size was not big enough, we did not perform subgroup analyses of various combinations.
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Univariate and multivariate Cox regression analyses for all-cause 28-day mortality

![](IJCCM-21-825-g002)

D[ISCUSSIONS]{.smallcaps} {#sec1-4}
=========================

In our retrospective study of patients with nonbacteremic carbapenem-resistant Gram-negative bacterial infections, colistin--carbapenem combination therapy (CCCT) was not superior to CMT. Combination therapy arm had higher all-cause 28-day mortality than the monotherapy arm. This was not unexpected in a retrospective study, with more number of sicker patients (in ICU and on inotropes) receiving combination therapy. Logistic regression analysis adjusting for the confounders including disease severity did not reveal any protective effect of combination therapy, denoting nonsuperiority of CCCT over CMT.

Carbapenem-resistant Gram-negative bacterial infections result in high morbidity and mortality of immunocompetent as well as immunocompromised patients. Various retrospective cohort studies and a few systematic reviews support the concept of CCT.\[[@ref4][@ref5][@ref6][@ref7][@ref8][@ref9][@ref10]\] At the same time, the only available meta-analysis on the subject could not demonstrate any superiority of the combination therapy over CMT.\[[@ref11]\] A large retrospective study of 661 patients with 447 bloodstream infections (Tumbarello *et al*.) found CCCT superior to CMT if the carbapenem MIC is \<8 mg/L.\[[@ref13]\] A recently published large multicenter study did not find colistin-based combination superior to monotherapy, except in a subgroup of patients with high pretreatment probability of death.\[[@ref14]\] A retrospective study of 91 patients with CRGNB bloodstream infections, from our own oncology center, found CMT to be as effective as CCCT, except in a subgroup of Enterobacteriaceae infections in neutropenia where the combination therapy arm had better outcome.\[[@ref12]\] We could find only two other combination studies from India, both small observational studies with no significant difference in the outcome between the two groups.\[[@ref15][@ref16]\] There are no published data from India comparing CCCT and CMT against CRGNB nonbacteremic infections. To the best of our knowledge, this is the first publication on combination therapy in nonbacteremic infections.

High carbapenem Minimum Inhibitory Concentration (MIC) (MIC \>16 mg/L) of most CRGNB isolates in the center (unpublished data), similar to available published data from other Indian centers, could possibly be one of the reasons for the lack of superiority of CCCT with carbapenem in comparison to CMT.\[[@ref15][@ref17]\] It is worth noting that even in the Tumbarello study, CCCT was superior only if the carbapenem MIC was \<8 mg/L.\[[@ref13]\]

Administration of appropriate antibiotic (an antibiotic sensitive against CRGNB) within 24 h of collection of the index isolate was also not associated with a protective effect in reducing mortality. This finding is similar to most other published studies on treatment of CRGNB infections, including the recently published large multicenter combination study that showed administration of antibiotics within the first 5 days (but not within the first 2 days) resulted in mortality reduction.\[[@ref6][@ref7][@ref9]\] We did not analyze the impact of appropriate antibiotic administration after 24 h (for example, within 2 days and within 5 days of index culture) which could have shown a protective effect of the appropriate antibiotic administration. High APACHE II score and *Klebsiella* as the etiologic agent were independently associated with higher 28-day all-cause mortality.

The main limitation of our study was the retrospective design and the inherent limitation of single-center data in solving combination therapy conundrum. To prevent the risk for spuriously significant associations between individual treatment regimens and mortality, retrospective observational studies on the monotherapy versus combination therapy may require several hundreds or thousands of patients. Only multicenter studies can achieve compilation of such a large data. Prospective randomized trials could be the ideal solution to the monotherapy versus combination therapy dilemma. We also need to explore the benefits of noncarbapenem-based combinations.
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In our retrospective, single-center series of carbapenem-resistant Gram-negative nonbacteremic infections, the outcome was similar in CCCT and CMT arms. Multicenter large observational studies or prospective randomized clinical trials are the need of the hour. The role of colistin-based combination with noncarbapenem antibiotics also needs to be explored.
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